益赛普对携带HLA-B27基因的未分化脊柱关节病患者的疗效  

Effect of Etanercept on undifferentiated spondyloarthropathies patients carrying HLA-B27 gene

作　　者：戴莉萍 何伟珍 孔卫红 尹志华 黄进贤 叶志中 

机构地区：[1]深圳市福田人民医院香蜜湖风湿病专科医院,广东深圳518040

出　　处：《中国热带医学》2014年第7期831-833,共3页China Tropical Medicine

基　　金：国家自然科学基金(No.81301529)

摘　　要：目的评价肿瘤坏死因子抑制剂益赛普治疗携带HLA-B27基因的未分化脊柱关节病(u SPA)患者的临床疗效和安全性。方法将56例HLA-B27阳性u Sp A患者分成两组,试验组36例应用生物制剂益赛普25mg/次,每周2次皮下注射,联合传统治疗方案慢作用改善病情药物+非甾类抗炎药(甲氨蝶呤10mg/周+美洛昔康7.5mg/d)治疗;对照组20例使用传统治疗方案,同等剂量甲氨蝶呤+美洛昔康治疗,疗程12周,记录各组治疗前后患者的症状、体征、疾病功能指数(BASFAI)、红细胞沉降率(ESR)及C-反应蛋白(CRP)等实验室指标及不良反应。结果试验组使用益赛普治疗1周,12周后患者的脊柱痛与夜间痛程度均明显改善,BASFAI、血沉、CRP均显著下降,与对照组比较差异有统计学意义(P<0.05)。试验组治疗12周后达到疗效20%、50%、70%改善的患者分别为34例(94.4%)、32例(88.9%)、29例(80.6%),均优于对照组(P<0.05)。不良反应主要为注射部位反应。结论益赛普治疗HLA-B27阳性u Sp A患者临床效果显著,安全性和耐受性好。Objective To evaluate the efficacy and safety of Etanereept in the treatment of undifferentiated spondyloarthropathies （uSpA） patients with positive HLA-B27. Methods The 56 uSpA patients carrying HLA-B27 were devided into experimental group（36 cases） and treated with combinated treatment of Etanercept and conventional medication （MTX10mg/w＋Meloxicam 7.5mg/d）and the control group （20 cases） treated with conventional medication. Activity and efficacy evaluation indexes were compared between the two groups after treatment for a course of 12 weeks.The therapeutic effect in both groups after treatment were observed and compared. Results The symptom, signs, functional index,erythroeyte sedimentation rate, level of C-reactive protein in case of experimental group were significantly improved a week and 12 weeks after treatment compared to those in the control group （P〈0.05）. Conclusion The efficacy of Etanercept was significant in treatment of uSpA patients carrying HLA-B27 with high safety and good tolerance.

关 键 词：未分化脊柱关节病 HLA—B27基因 益赛普 

分 类 号：R684[医药卫生—骨科学]